Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases

[1]  M. Eki̇m,et al.  Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis , 2016, Clinical Rheumatology.

[2]  P. Hawkins,et al.  Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. , 2015, Clinical and experimental rheumatology.

[3]  S. Ozen,et al.  Anti-interleukin 1 treatment in secondary renal amyloidosis associated with autoinflammatory diseases , 2015, Pediatric Rheumatology Online Journal.

[4]  D. Rigante,et al.  Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab , 2015, Clinical Rheumatology.

[5]  Serena Wong,et al.  Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome , 2015, BMC Nephrology.

[6]  R. Cimaz,et al.  Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations , 2015, Expert review of clinical immunology.

[7]  P. Hawkins,et al.  Emerging treatments for amyloidosis. , 2015, Kidney international.

[8]  M. Fändrich,et al.  AA amyloidosis: pathogenesis and targeted therapy. , 2015, Annual review of pathology.

[9]  D. Real de Asúa,et al.  Systemic AA amyloidosis: epidemiology, diagnosis, and management , 2014, Clinical epidemiology.

[10]  M. Lidar,et al.  Cryopyrin-associated periodic syndrome. , 2014, The Israel Medical Association journal : IMAJ.

[11]  C. Wallace,et al.  Judicious Use of Biologicals in Juvenile Idiopathic Arthritis , 2014, Current Rheumatology Reports.

[12]  Tomoyuki Saito,et al.  Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis , 2014, The Journal of Rheumatology.

[13]  M. Pepys,et al.  Targeted treatment for amyloidosis. , 2014, The Israel Medical Association journal : IMAJ.

[14]  R. Cron,et al.  Treatment of juvenile idiopathic arthritis: a revolution in care , 2014, Pediatric Rheumatology.

[15]  S. Ozen,et al.  A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin , 2014, Nature Reviews Rheumatology.

[16]  Francis Guillemin,et al.  Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. , 2014, Joint, bone, spine : revue du rhumatisme.

[17]  C. Wouters,et al.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[18]  Y. Caliskan,et al.  Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever , 2012, Rheumatology International.

[19]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[20]  D. Kastner,et al.  Lighting the fires within: the cell biology of autoinflammatory diseases , 2012, Nature Reviews Immunology.

[21]  Sampath Prahalad,et al.  Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritis , 2012, Arthritis care & research.

[22]  S. Özen,et al.  Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review , 2012, Annals of the rheumatic diseases.

[23]  C. Baldari,et al.  Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene , 2012, Rheumatology International.

[24]  S. Özen,et al.  Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. , 2012, Gene.

[25]  P. Hawkins,et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.

[26]  D. Kastner,et al.  Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade , 2011, Proceedings of the National Academy of Sciences.

[27]  Andrew I. Shulman,et al.  Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. , 2011, Arthritis and rheumatism.

[28]  A. Petrie,et al.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits , 2010, Nature.

[29]  S. Şen,et al.  A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report. , 2010, Archives of pathology & laboratory medicine.

[30]  A. Petrie,et al.  Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis , 2010, British journal of haematology.

[31]  G. Merlini,et al.  Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. , 2009, Arthritis and rheumatism.

[32]  L. Dave,et al.  Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis , 2009, Lung India : official organ of Indian Chest Society.

[33]  G. Pohl,et al.  Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  R. Goldbach-Mansky,et al.  The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies , 2008, Current allergy and asthma reports.

[35]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[36]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[37]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[38]  C. Duarte,et al.  Renal amyloidosis: an uncommon complication of juvenile idiopathic arthritis , 2006, Clinical Rheumatology.

[39]  G. Merlini,et al.  Clinical aspects of systemic amyloid diseases. , 2005, Biochimica et biophysica acta.

[40]  G. Hitman,et al.  Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis , 2004, Genes and Immunity.

[41]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[42]  P. Hawkins,et al.  AA amyloidosis complicating the hereditary periodic fever syndromes. , 2003, Arthritis and rheumatism.

[43]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[44]  L. Memış,et al.  Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever , 2003, Pediatric Nephrology.

[45]  J. Kemp,et al.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis , 2002, Nature.

[46]  R. Kolodner,et al.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome , 2001, Nature Genetics.

[47]  L. Lovat,et al.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.

[48]  S. Urieli-Shoval,et al.  Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states , 2000, Current opinion in hematology.

[49]  M. Suarez‐Almazor,et al.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. , 1998, The Journal of rheumatology.

[50]  L. Lovat,et al.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. David.  Amyloidosis in juvenile chronic arthritis. , 1991, Clinical and experimental rheumatology.